guest ::
| Home > In process > Persistent viral control status is associated with enhanced innate immune responses in people with HIV-1 > print |
| Home > In process > Persistent viral control status is associated with enhanced innate immune responses in people with HIV-1 > print |
| 001 | 285369 | ||
| 005 | 20260302150041.0 | ||
| 024 | 7 | _ | |a 10.1016/j.isci.2026.114807 |2 doi |
| 037 | _ | _ | |a DZNE-2026-00233 |
| 082 | _ | _ | |a 050 |
| 100 | 1 | _ | |a C. dos Santos, Jéssica |b 0 |
| 245 | _ | _ | |a Persistent viral control status is associated with enhanced innate immune responses in people with HIV-1 |
| 260 | _ | _ | |a St. Louis |c 2026 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1772459871_18950 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The mechanisms mediating elite and persistent HIV control in people living with HIV (PLHIV) are only partially understood and largely attributed to adaptive T cell responses, but whether innate immunity also contributes remains unclear. Using samples from the 2000HIV study, we examined the transcriptional and functional profiles of monocytes from spontaneous HIV controllers and normal progressors on long-term antiretroviral therapy. HIV controllers displayed enhanced cytokine production after bacterial and viral stimulation, alongside antiviral and interferon-inducible transcriptional signatures and reduced inflammatory gene expression. Persistent controllers further showed increased capacity for trained immunity, with H3K4me3 profiling indicating the epigenetic priming of innate immune genes. Remarkably, relatives of persistent controllers also exhibited stronger innate and trained immune responses than relatives of normal progressors. These findings suggest that robust innate immunity, particularly monocyte function, may precede infection and contribute to sustained HIV control, offering new avenues for therapies that induce similar innate antiviral responses. |
| 536 | _ | _ | |a 354 - Disease Prevention and Healthy Aging (POF4-354) |0 G:(DE-HGF)POF4-354 |c POF4-354 |f POF IV |x 0 |
| 536 | _ | _ | |a 351 - Brain Function (POF4-351) |0 G:(DE-HGF)POF4-351 |c POF4-351 |f POF IV |x 1 |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 2 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 693 | _ | _ | |0 EXP:(DE-2719)PRECISE-20190321 |5 EXP:(DE-2719)PRECISE-20190321 |e Platform for Single Cell Genomics and Epigenomics at DZNE University of Bonn |x 0 |
| 700 | 1 | _ | |a Groenendijk, Albert L. |b 1 |
| 700 | 1 | _ | |a Ruijten, Suzanne D. E. |b 2 |
| 700 | 1 | _ | |a Knoll, Rainer |0 P:(DE-2719)9000620 |b 3 |u dzne |
| 700 | 1 | _ | |a Vadaq, Nadira |b 4 |
| 700 | 1 | _ | |a Horst, Rob ter |b 5 |
| 700 | 1 | _ | |a Fok, Ezio T. |b 6 |
| 700 | 1 | _ | |a Witkowski, Wojciech |b 7 |
| 700 | 1 | _ | |a Blaauw, Marc J. T. |b 8 |
| 700 | 1 | _ | |a van Eekeren, Louise E. |b 9 |
| 700 | 1 | _ | |a Vos, Wilhelm A. J. W. |b 10 |
| 700 | 1 | _ | |a Cleophas-Jacobs, Maartje |b 11 |
| 700 | 1 | _ | |a Reichl, Stephan |b 12 |
| 700 | 1 | _ | |a Otten, Twan |b 13 |
| 700 | 1 | _ | |a Martens, Joost H. A. |b 14 |
| 700 | 1 | _ | |a van der Meer, Arnold |b 15 |
| 700 | 1 | _ | |a Koninkx, Han |b 16 |
| 700 | 1 | _ | |a de Jonge, Marien I. |b 17 |
| 700 | 1 | _ | |a Beyer, Marc D. |0 P:(DE-2719)2812219 |b 18 |u dzne |
| 700 | 1 | _ | |a van Lunzen, Jan |b 19 |
| 700 | 1 | _ | |a Joosten, Leo A. B. |b 20 |
| 700 | 1 | _ | |a Bock, Christoph |b 21 |
| 700 | 1 | _ | |a Rokx, Casper |b 22 |
| 700 | 1 | _ | |a Verbon, Annelies |b 23 |
| 700 | 1 | _ | |a Vandekerckhove, Linos |b 24 |
| 700 | 1 | _ | |a Aschenbrenner, Anna C. |0 P:(DE-2719)2812913 |b 25 |u dzne |
| 700 | 1 | _ | |a Schultze, Joachim L. |0 P:(DE-2719)2811660 |b 26 |u dzne |
| 700 | 1 | _ | |a Matzaraki, Vasiliki |b 27 |
| 700 | 1 | _ | |a van der Ven, Andre J. A. M. |b 28 |
| 700 | 1 | _ | |a Netea, Mihai G. |b 29 |
| 773 | _ | _ | |a 10.1016/j.isci.2026.114807 |g Vol. 29, no. 3, p. 114807 - |0 PERI:(DE-600)2927064-9 |n 3 |p 114807 |t iScience |v 29 |y 2026 |x 2589-0042 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285369/files/DZNE-2026-00233.pdf |y Restricted |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285369/files/DZNE-2026-00233.pdf?subformat=pdfa |x pdfa |y Restricted |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9000620 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2812219 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 25 |6 P:(DE-2719)2812913 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 26 |6 P:(DE-2719)2811660 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-354 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Prevention and Healthy Aging |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-351 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Brain Function |x 1 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 2 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ISCIENCE : 2022 |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2025-08-21T14:52:29Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2025-08-21T14:52:29Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2025-08-21T14:52:29Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-11-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-11-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ISCIENCE : 2022 |d 2025-11-10 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2025-11-10 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2025-11-10 |
| 920 | 1 | _ | |0 I:(DE-2719)5000082 |k AG Aschenbrenner |l Aging and Immunity |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1013035 |k AG Beyer |l Immunogenomics and Neurodegeneration |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1013038 |k AG Schultze |l Clinical Single Cell Omics (CSCO) / Systems Medicine |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)1013031 |k PRECISE |l Platform for Single Cell Genomics and Epigenomics |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)5000082 |
| 980 | _ | _ | |a I:(DE-2719)1013035 |
| 980 | _ | _ | |a I:(DE-2719)1013038 |
| 980 | _ | _ | |a I:(DE-2719)1013031 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|